过去 90 天内没有内部人买入。最近一笔由 NELSON TIMOTHY S 披露于 2021年11月22日。
Impel Neuropharma Inc：高管交易动态
Impel Neuropharma Inc归属医疗与制药行业。公司董事和高级管理人员通过SEC (Form 4)申报交易。Impel Neuropharma Inc已超过一年没有高管申报，最近一份可追溯到2024年4月9日。
回溯至覆盖起点2021年，高管共申报10笔买入和6笔卖出。
以上数据均来自SEC (Form 4)发布的申报，描述的是过去的情况，不代表未来股价走势，也不构成投资建议。
该评分只在所属市场内对买入进行排名。仅在经过回测的策略范围内的交易所提供建议仓位；其他市场的信号仍处于观察状态。并非投资建议。
财务数据
财年 2022财年截至 2022年12月 · cache
- 10,000 股0股票SEC:0001415889-24-010567:0
- 12,066 股@ US$0.290.0% 占其流量股票SEC:0001213900-23-097043:1
- 209,029 股@ US$0.110.3% 占其流量股票SEC:0001213900-23-097043:2
- 28,682 股@ US$0.110.0% 占其流量股票SEC:0001213900-23-097043:3
- 208,657 股@ US$0.080.2% 占其流量股票SEC:0001213900-23-097043:4
- 28,632 股@ US$0.080.0% 占其流量股票SEC:0001213900-23-097043:5
- 87,934 股@ US$0.29100.0% 占其流量股票SEC:0001213900-23-097043:0
- 3,627 股@ US$3.75100.0% 占其流量股票SEC:0001209191-23-001365:1
- 10,571 股0股票SEC:0001209191-23-001365:0
- 24,606 股@ US$1.9763.8% 占其流量股票SEC:0001209191-22-021673:0
- 20,000 股@ US$1.64100.0% 占其流量股票SEC:0001209191-21-071087:0
- 10,000 股@ US$10.7554100.0% 占其流量股票SEC:0001209191-21-066134:0标准退出：2022年2月17日 (T+90)
- 4,650 股@ US$2.464.6% 占其流量股票SEC:0001209191-21-057275:1
- 53,954 股@ US$2.9563.4% 占其流量股票SEC:0001209191-21-057275:2
- 14,780 股@ US$1.9736.2% 占其流量股票SEC:0001209191-21-057275:0
- 2,197 股@ US$14.9111.7% 占其流量股票SEC:0001209191-21-052595:1标准退出：2021年11月16日 (T+90)
- 600 股@ US$15.893.4% 占其流量股票SEC:0001209191-21-052595:2标准退出：2021年11月16日 (T+90)
- 17,203 股@ US$13.8061100.0% 占其流量股票SEC:0001209191-21-052595:0标准退出：2021年11月16日 (T+90)
- 4,253 股0股票SEC:0001209191-21-038665:0
- 118,712 股@ US$13.508.9% 占其流量股票SEC:0001140361-21-014994:1
- 1,100,000 股@ US$15.0091.1% 占其流量股票SEC:0001140361-21-014994:2标准退出：2021年7月26日 (T+90)
- 89,145 股@ US$13.5012.0% 占其流量股票SEC:0001213900-21-023652:8
- 12,311 股@ US$13.501.7% 占其流量股票SEC:0001213900-21-023652:9
- 505,620 股@ US$15.0075.7% 占其流量股票SEC:0001213900-21-023652:10标准退出：2021年7月26日 (T+90)
- 69,380 股@ US$15.0010.4% 占其流量股票SEC:0001213900-21-023652:11标准退出：2021年7月26日 (T+90)
53 条申报中的 25 条
About Impel Neuropharma Inc
Impel NeuroPharma Inc. (ticker IMPL) is a U.S.-listed biopharmaceutical company that trades on NASDAQ; it later changed its corporate name to Impel Pharmaceuticals in 2022, but many market references and SEC records still reflect the former name. For francophone investors, the company sits squarely in the health-care/pharma universe, with a business model built around drug-delivery innovation rather than a broad diversified pipeline. Impel was incorporated in Delaware on July 24, 2008, and its headquarters and principal operations are in Seattle, Washington, in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1445499/000095017023021513/impl-20230331.htm?utm_source=openai))
The company’s core differentiation has been its proprietary Precision Olfactory Delivery (POD) platform, designed to deliver therapies through the nasal route for rapid absorption and patient convenience. Historically, Impel described itself as a late-stage or commercial-stage biopharmaceutical company focused on transformative therapies for diseases with high unmet medical needs, initially with an emphasis on central nervous system disorders. Its lead commercial product is Trudhesa™ (dihydroergotamine mesylate) Nasal Spray, approved in the U.S. for migraine treatment and central to the company’s commercialization efforts. Beyond this asset, Impel has discussed additional product candidates and broader applications for its POD technology, but the economic profile has remained highly concentrated. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1445499/000095017022009951/impl-20220331.htm?utm_source=openai))
展开全文收起
From a competitive standpoint, Impel operates as a niche specialty pharma company where execution matters more than scale. Its competitive edge depends on clinical differentiation, prescriber adoption, reimbursement access, and the ability to translate a delivery-platform advantage into sustainable revenues. Rather than competing head-on with large diversified pharmaceutical companies, it is better viewed against migraine, neurology, and specialty-drug peers. The strategic logic is clear: one marketed product provides near-term commercial proof, while the POD platform offers optionality for future expansion into additional indications if development and commercialization efforts succeed. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1445499/000095017022009951/impl-20220331.htm?utm_source=openai))
Geographically, the company is primarily U.S.-centric: it is NASDAQ-listed, headquartered in Seattle, and focused on the U.S. market for commercial execution. SEC filings also note certain research and development activities in Australia, indicating that development operations have not been entirely domestic. Recent company disclosures and filings have highlighted financing activity, commercialization of Trudhesa, and balance-sheet management—typical themes for a small-cap biotech transitioning from development into commercial execution. For investors, the key variables remain product sales traction, regulatory and market-access execution, and the company’s ability to broaden its platform beyond a single core asset. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1445499/000119312521269949/d593533d424b4.htm?utm_source=openai))
